A prospective controlled evaluation of winterized Pistacia lentiscus oil nasal spray in vasomotor rhinitis
9 affiliations
- 1Department of Biomolecular Sciences, University of Urbino “Carlo Bo” , ,
- 2Microbiota International Clinical Society , ,
- 3Department of Clinical and Experimental Medicine, University of Foggia , ,
- 4Faculty of Medicine and Surgery, University of Enna “Kore” , ,
- 5Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Pisa University Hospital , ,
- 6Department of Oral and Maxillofacial Sciences, Sapienza University , ,
- 7Department of Sense Organs, Sapienza University , ,
- 8Department of Biochemistry, Liaquat University of Medical and Health Sciences (LUMHS) , ,
- 9Ent Clinic ASST Settelaghi, University of Insubriae Varese , ,
Abstract
Background
Vasomotor rhinitis (VMR), currently included within the broader spectrum of non-allergic rhinopathy, is a chronic condition characterized by nasal obstruction, rhinorrhea, and hyperreactivity to non-specific environmental triggers. Although traditionally considered a neurovascular disorder driven by autonomic dysregulation, emerging evidence suggests that mucosal inflammatory and microbial factors may contribute to symptom persistence in selected patients. Winterized Pistacia lentiscus oil has demonstrated antimicrobial and anti-biofilm properties in upper airway experimental models, suggesting potential therapeutic relevance in chronic nasal disorders.Methods
This prospective controlled study evaluated the effectiveness of a nasal spray medical device containing winterized Pistacia lentiscus oil (Bactorinol® nasal spray, PharmExtracta S.p.A., Italy) in patients with VMR. A total of 120 participants were enrolled, with 110 completing the study (58 treated, 52 controls). Primary endpoints included changes in Peak Nasal Inspiratory Flow (PNIF) and symptom burden assessed using the Sino-Nasal Outcome Test (SNOT-22). Secondary endpoints included nasal cytological assessment of inflammatory cellularity (neutrophils, eosinophils, mast cells), bacterial abundance, supranuclear stria, and cytological findings compatible with biofilm-like structures. Repeated-measures General Linear Models were used to evaluate treatment effects over time.Results
Compared with controls, treated patients demonstrated significantly greater clinical improvement over the study period. SNOT-22 scores decreased by 30.5% in the treatment group versus 9.7% in controls (time × group interaction, p < 0.001). PNIF improved by 44.5% in treated subjects compared with 20.8% in controls (p = 0.006 for interaction). Significant treatment-associated reductions were also observed for neutrophils (p = 0.001), mast cells (p = 0.021), bacterial abundance (p = 0.002), and cytological findings compatible with biofilm-like structures (p = 0.001). Although the treatment group presented a higher baseline burden for several parameters, post-treatment outcomes favored the intervention group.Conclusions
Winterized Pistacia lentiscus oil nasal spray was associated with significant improvements in symptoms, nasal airflow, inflammatory cytology, and microbial-related cytological findings in patients with VMR. These findings support the hypothesis that selected phenotypes of non-allergic nasal disease may involve mucosal inflammatory and microbial components beyond classical neurovascular dysfunction. Larger randomized studies with microbiological and molecular characterization are warranted to confirm these preliminary findings and clarify mechanisms of action.
Related
- Evaluation of Intraperitoneal Instillation Combined with Port-Site Infiltration of 0.5% Bupivacaine for Postoperative Pain Management in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial
- Non-Hormonal Psychopharmacotherapy of Vasomotor Symptoms Related to Menopause
- Acetylcholine Provocation Testing for Coronary Vasomotor Disorders
- Estradiol for persistent vasomotor symptoms after surgical menopause in a transgender man
- Neurokinin-3 receptor antagonists for vasomotor symptoms in menopause and breast cancer survivorship.
BibTeX
@article{bertuccioli2026prospective,
title = {{A prospective controlled evaluation of winterized Pistacia lentiscus oil nasal spray in vasomotor rhinitis}},
author = {Alexander Bertuccioli and Annalisa Belli and Davide Sisti and Marco B. L. Rocchi and Chiara M. Palazzi and Matteo Gelardi and Ignazio La Mantia and Veronica Seccia and Simonetta Masieri and Elona Begvarfaj and Amjad Khan and Alberto Macchi},
journal = {Frontiers in allergy},
year = {2026},
month = oct,
doi = {10.3389/falgy.2026.1946438},
url = {https://europepmc.org/article/PMC/PMC13716554},
note = {CC BY},
}
RIS
TY - JOUR
TI - A prospective controlled evaluation of winterized Pistacia lentiscus oil nasal spray in vasomotor rhinitis
AU - Alexander Bertuccioli
AU - Annalisa Belli
AU - Davide Sisti
AU - Marco B. L. Rocchi
AU - Chiara M. Palazzi
AU - Matteo Gelardi
AU - Ignazio La Mantia
AU - Veronica Seccia
AU - Simonetta Masieri
AU - Elona Begvarfaj
AU - Amjad Khan
AU - Alberto Macchi
PY - 2026
DA - 2026/10/15
JO - Frontiers in allergy
DO - 10.3389/falgy.2026.1946438
UR - https://europepmc.org/article/PMC/PMC13716554
AB - Background Vasomotor rhinitis (VMR), currently included within the broader spectrum of non-allergic rhinopathy, is a chronic condition characterized by nasal obstruction, rhinorrhea, and hyperreactivity to non-specific environmental triggers. Although traditionally considered a neurovascular disorder driven by autonomic dysregulation, emerging evidence suggests that mucosal inflammatory and microbial factors may contribute to symptom persistence in selected patients. Winterized Pistacia lentiscus oil has demonstrated antimicrobial and anti-biofilm properties in upper airway experimental models, suggesting potential therapeutic relevance in chronic nasal disorders.Methods This prospective controlled study evaluated the effectiveness of a nasal spray medical device containing winterized Pistacia lentiscus oil (Bactorinol® nasal spray, PharmExtracta S.p.A., Italy) in patients with VMR. A total of 120 participants were enrolled, with 110 completing the study (58 treated, 52 controls). Primary endpoints included changes in Peak Nasal Inspiratory Flow (PNIF) and symptom burden assessed using the Sino-Nasal Outcome Test (SNOT-22). Secondary endpoints included nasal cytological assessment of inflammatory cellularity (neutrophils, eosinophils, mast cells), bacterial abundance, supranuclear stria, and cytological findings compatible with biofilm-like structures. Repeated-measures General Linear Models were used to evaluate treatment effects over time.Results Compared with controls, treated patients demonstrated significantly greater clinical improvement over the study period. SNOT-22 scores decreased by 30.5% in the treatment group versus 9.7% in controls (time × group interaction, p < 0.001). PNIF improved by 44.5% in treated subjects compared with 20.8% in controls (p = 0.006 for interaction). Significant treatment-associated reductions were also observed for neutrophils (p = 0.001), mast cells (p = 0.021), bacterial abundance (p = 0.002), and cytological findings compatible with biofilm-like structures (p = 0.001). Although the treatment group presented a higher baseline burden for several parameters, post-treatment outcomes favored the intervention group.Conclusions Winterized Pistacia lentiscus oil nasal spray was associated with significant improvements in symptoms, nasal airflow, inflammatory cytology, and microbial-related cytological findings in patients with VMR. These findings support the hypothesis that selected phenotypes of non-allergic nasal disease may involve mucosal inflammatory and microbial components beyond classical neurovascular dysfunction. Larger randomized studies with microbiological and molecular characterization are warranted to confirm these preliminary findings and clarify mechanisms of action.
SN - 2673-6101
ER -